PGS Publication: PGP000123

Publication Information (EuropePMC)
Title Genetic and Circulating Biomarker Data Improve Risk Prediction for Pancreatic Cancer in the General Population.
PubMed ID 32321713(Europe PMC)
doi 10.1158/1055-9965.epi-19-1389
Publication Date April 22, 2020
Journal Cancer Epidemiol Biomarkers Prev
Author(s) Kim J, Yuan C, Babic A, Bao Y, Clish CB, Pollak MN, Amundadottir LT, Klein AP, Stolzenberg-Solomon RZ, Pandharipande PV, Brais LK, Welch MW, Ng K, Giovannucci EL, Sesso HD, Manson JE, Stampfer MJ, Fuchs CS, Wolpin BM, Kraft P.
Released in PGS Catalog: Jan. 7, 2021

Associated Polygenic Score(s)

Filter PGS by Participant Ancestry
Individuals included in:
G - Source of Variant Associations (GWAS)
D - Score Development/Training
E - PGS Evaluation
List of ancestries includes:
Display options:
Ancestry legend
Multi-ancestry (including European)
Multi-ancestry (excluding European)
African
East Asian
South Asian
Additional Asian Ancestries
European
Greater Middle Eastern
Hispanic or Latin American
Additional Diverse Ancestries
Not Reported

PGS Developed By This Publication

Polygenic Score ID & Name PGS Publication ID (PGP) Reported Trait Mapped Trait(s) (Ontology) Number of Variants Ancestry distribution PGS Scoring File (FTP Link)
PGS000663
(wGRS22)
PGP000123 |
Kim J et al. Cancer Epidemiol Biomarkers Prev (2020)
Pancreatic cancer pancreatic carcinoma 22
-
http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000663/ScoringFiles/PGS000663.txt.gz

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance
Metric ID (PPM)
Evaluated Score PGS Sample Set ID
(PSS)
Performance Source Trait PGS Effect Sizes
(per SD change)
Classification Metrics Other Metrics Covariates Included in the Model PGS Performance:
Other Relevant Information
PPM001367 PGS000663
(wGRS22)
PSS000598|
European Ancestry|
1,591 individuals
PGP000123 |
Kim J et al. Cancer Epidemiol Biomarkers Prev (2020)
Reported Trait: Pancreatic cancer OR: 1.37 [1.23, 1.53] Cross validation approach-testing sample = 20%
PPM001368 PGS000663
(wGRS22)
PSS000597|
European Ancestry|
956 individuals
PGP000123 |
Kim J et al. Cancer Epidemiol Biomarkers Prev (2020)
Reported Trait: Pancreatic cancer (0-10 years of follow-up) OR: 1.46 [1.27, 1.68] Cross validation approach-testing sample = 20%
PPM001369 PGS000663
(wGRS22)
PSS000598|
European Ancestry|
1,591 individuals
PGP000123 |
Kim J et al. Cancer Epidemiol Biomarkers Prev (2020)
Reported Trait: Pancreatic cancer OR: 1.37 [1.22, 1.53] AUROC: 0.65 matching factors, age, cohort (also gender), race/ethnicity, smoking status, fasting status, month/year of blood collection, body mass index, waist-to-hip ratio, diabetic status Cross validation approach-testing sample = 20%
PPM001370 PGS000663
(wGRS22)
PSS000597|
European Ancestry|
956 individuals
PGP000123 |
Kim J et al. Cancer Epidemiol Biomarkers Prev (2020)
Reported Trait: Pancreatic cancer (0-10 years of follow-up) OR: 1.44 [1.25, 1.67] AUROC: 0.67 matching factors, age, cohort (also gender), race/ethnicity, smoking status, fasting status, month/year of blood collection, body mass index, waist-to-hip ratio, diabetic status Cross validation approach-testing sample = 20%

Evaluated Samples

PGS Sample Set ID
(PSS)
Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS000597 In this study, cases were incident patients with primary pancreatic adenocarcinoma ascertained between 1984 and 2010 through self- report, report of next-of-kin, or death certificates and confirmed by medical record review and tumor registry data. Cases Diagnosed within 10 years of blood collection. Mean = 10.0 years
[
  • 304 cases
  • , 652 controls
]
,
28.1 % Male samples
European HPFS, NHS, PHS, WHI Overlap with GWAS samples (percentage unknown). Cross validation approach used (20% as testing sample)
PSS000598 In this study, cases were incident patients with primary pancreatic adenocarcinoma ascertained between 1984 and 2010 through self- report, report of next-of-kin, or death certificates and confirmed by medical record review and tumor registry data.
[
  • 500 cases
  • , 1,091 controls
]
,
33.4 % Male samples
European HPFS, NHS, PHS, WHI Overlap with GWAS samples (percentage unknown). Cross validation approach used (20% as testing sample)